238 related articles for article (PubMed ID: 25755077)
1. Radioiodine remnant ablation in low-risk differentiated thyroid cancer patients who had R0 dissection is an over treatment.
Bal C; Ballal S; Soundararajan R; Chopra S; Garg A
Cancer Med; 2015 Jul; 4(7):1031-8. PubMed ID: 25755077
[TBL] [Abstract][Full Text] [Related]
2. Intermediate-risk differentiated thyroid carcinoma patients who were surgically ablated do not need adjuvant radioiodine therapy: long-term outcome study.
Ballal S; Soundararajan R; Garg A; Chopra S; Bal C
Clin Endocrinol (Oxf); 2016 Mar; 84(3):408-16. PubMed ID: 25823589
[TBL] [Abstract][Full Text] [Related]
3. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer.
Tsirona S; Vlassopoulou V; Tzanela M; Rondogianni P; Ioannidis G; Vassilopoulos C; Botoula E; Trivizas P; Datseris I; Tsagarakis S
Clin Endocrinol (Oxf); 2014 Mar; 80(3):459-63. PubMed ID: 23895145
[TBL] [Abstract][Full Text] [Related]
4. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
5. Radioiodine remnant ablation in low-risk differentiated thyroid cancer.
Saengsuda Y
J Med Assoc Thai; 2013 May; 96(5):614-24. PubMed ID: 23745318
[TBL] [Abstract][Full Text] [Related]
6. Low-risk differentiated thyroid cancer and radioiodine remnant ablation: a systematic review of the literature.
Lamartina L; Durante C; Filetti S; Cooper DS
J Clin Endocrinol Metab; 2015 May; 100(5):1748-61. PubMed ID: 25679996
[TBL] [Abstract][Full Text] [Related]
7. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation.
Vrachimis A; Schober O; Riemann B
Nuklearmedizin; 2012; 51(3):67-72. PubMed ID: 22294096
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
9. Low versus high activity radioiodine remnant ablation for differentiated thyroid carcinoma with gross extrathyroidal extension invading only strap muscles.
Park SY; Kim HI; Choi JY; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Ahn SH; Kim K; Jeong JG; Kim SW; Chung JH; Kim TH
Oral Oncol; 2018 Sep; 84():41-45. PubMed ID: 30115474
[TBL] [Abstract][Full Text] [Related]
10. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal.
Tuttle RM; Brokhin M; Omry G; Martorella AJ; Larson SM; Grewal RK; Fleisher M; Robbins RJ
J Nucl Med; 2008 May; 49(5):764-70. PubMed ID: 18413378
[TBL] [Abstract][Full Text] [Related]
11. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
[TBL] [Abstract][Full Text] [Related]
12. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation.
Robbins RJ; Larson SM; Sinha N; Shaha A; Divgi C; Pentlow KS; Ghossein R; Tuttle RM
J Nucl Med; 2002 Nov; 43(11):1482-8. PubMed ID: 12411552
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of radioiodine remnant ablation for differentiated thyroid carcinoma patients with an incomplete thyroidectomy.
Hfu H; Ma C; Li J; Feng F; Wu S; Ye Z; Wang H
Q J Nucl Med Mol Imaging; 2016 Sep; 60(3):280-4. PubMed ID: 25192307
[TBL] [Abstract][Full Text] [Related]
14. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.
Jarzab B; Handkiewicz-Junak D; Wloch J
Endocr Relat Cancer; 2005 Dec; 12(4):773-803. PubMed ID: 16322322
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human thyroid stimulating hormone-assisted radioactive iodine remnant ablation in thyroid cancer patients at intermediate to high risk of recurrence.
Hugo J; Robenshtok E; Grewal R; Larson S; Tuttle RM
Thyroid; 2012 Oct; 22(10):1007-15. PubMed ID: 22873801
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy.
Súss SKA; Mesa CO; Carvalho GA; Miasaki FY; Chaves CP; Fuser DC; Corbo R; Momesso D; Bulzico DA; Graf H; Vaisman F
Arch Endocrinol Metab; 2018; 62(2):149-156. PubMed ID: 29641738
[TBL] [Abstract][Full Text] [Related]
17. Radioiodine remnant ablation: current indications and dosing regimens.
Haugen BR
Endocr Pract; 2012; 18(4):604-10. PubMed ID: 22849876
[TBL] [Abstract][Full Text] [Related]
18. Indication for radioiodine remnant ablation in differentiated thyroid cancer patients: does 2018 Italian consensus change anything?
Forleo R; Fralassi N; Maino F; Capezzone M; Brilli L; Pilli T; Cantara S; Castagna MG
J Endocrinol Invest; 2021 Jan; 44(1):139-144. PubMed ID: 32388842
[TBL] [Abstract][Full Text] [Related]
19. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
[TBL] [Abstract][Full Text] [Related]
20. Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years.
Molinaro E; Pieruzzi L; Viola D
J Endocrinol Invest; 2012; 35(6 Suppl):16-20. PubMed ID: 23014069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
